John Kappos
610 Newport Center Drive, 17th Floor
Newport Beach, CA, 92660
Phone: +1-949-823-6954
Fax: +1-949-823-6994
-
Warren T. Lazarow
2765 Sand Hill Road
Menlo Park, CA, 94025
Phone: +1-650-473-2637
Fax: +1-650-473-2601
-
David Murphy
610 Newport Center Drive, 17th Floor
Newport Beach, CA, 92660
Phone: +1-949-823-6960
Fax: +1-949-823-6994
-
Sam Zucker
2765 Sand Hill Road
Menlo Park, CA, 94025
Phone: +1-650-473-2638
Fax: +1-650-473-2601
PROFESSIONALS
- Related Practices
-
Affymetrix, Inc.
Ajinomoto Co., Inc.
Amylin Pharmaceuticals, Inc.
Cell Genesys
Celula, Inc.
Clontech Laboratories, Inc.
Cogentus Pharmaceuticals Inc.
Insite Vision
Johnson & Johnson
Merck & Co., Inc.
Nanogen, Inc.
Nektar Therapeutics
New Leaf Venture Partners
Novartis Vaccines and Diagnostics
SentreHeart, Inc.
Sirna Therapeutics
Sprout Group
Transcept Pharmaceuticals, Inc.
Vicuron Pharmaceuticals, Inc.
WuXi Pharmatech Co., Ltd.
|
Life Sciences
Key Facts
- Our life sciences lawyers are recognized for their leadership by such national and international publications as Chambers and Partners, The Legal 500, Forbes, and the San Francisco Daily Journal.
- Many of our lawyers hold advanced scientific degrees or have worked in-house — permitting us to offer practical counseling backed by real world experience.
- Our ability to navigate complex issues at the intersection of seemingly disparate locations and business sectors makes us the lawyers to see for the most ambitious global and cross-border transactions, as with our representation of WuXi PharmaTech (Cayman) Inc., the leading China-based pharmaceutical and biotechnology research and development outsourcing company, in its US$212 million initial public offering on the New York Stock Exchange.
- We appreciate the high-risk environment that life sciences companies face. With decades of experience litigating high-stakes matters, including multi-venued, high-profile, pharmaceutical, products liability, and patent litigations, we have the insight needed to provide solid strategic advice to clients on the verge of acquiring new technology, or launching a new product -- placing them ahead of the curve on risk assessment, management and avoidance.
- Indeed, O’Melveny’s compelling mix of industry experience, intellectual property strength, and first-class Asian and European resources offers life sciences clients a competitive edge in the dynamic and ever-changing life sciences landscape -- and we are proud of our long track record of providing integrated, comprehensive, and coordinated representation on the most complex and high-profile biotech and life sciences matters.
- Our work on a recent US$1.1 billion acquisition of an RNA interference technology company, for example, involved lawyers from four of our offices collaborating seamlessly on antitrust, tax, intellectual property, and labor law issues.
- In December 2006, we represented venture capital investor The Sprout Group in the US$100 million financing of Kalypsys, named the largest private biotech financing of 2006 by The Deal. One month later, we represented a consortium of venture capital investors in the largest private biotech financing in history: the US$670 million “minnow-swallows-whale” acquisition financing of Ikaria.
- Over the past 30 years, we have defended hundreds of consumer class actions in 45 states and regularly serve as lead counsel to large pharmaceutical and medical device companies in high-profile mass tort proceedings, class actions, and government enforcement actions, including wrongful death and personal injury cases.
- We also have extensive experience litigating multi-faceted intellectual property and technology disputes in forums around the nation. Our work for OrthoClear is but one example in which we successfully handled related matters simultaneously pending in multiple state and federal courts and the International Trade Commission.
Industry Reach
We represent clients in a wide range of industries, including:
- Biotechnology
- Drug discovery
- Genomics
- Medical devices
- Nanotechnology
- Pharmaceuticals
|
B. Braun (Central Admixture Pharmacy Services, Inc.)
Fabrus
Vicuron Pharmaceuticals, Inc.
OrthoClear, Inc.
Sirna Therapeutics
New Leaf Venture Partners
Affymetrix, Inc
Clontech Laboratories, Inc.
|